ÇѸ²´ëÇб³¼º½Éº´¿ø

Àå´ë¿µ ±³¼ö

fhdzang@hallym.or.kr
  • Áø·á°ú Ç÷¾×Á¾¾ç³»°ú

Àü¹®Áø·áºÐ¾ß

À§¡¤´ëÀ塤°£¡¤ÃéÀ塤´ãµµ¡¤GIST ¼ÒÈ­±â¾Ï, ¸¸¼º¹éÇ÷º´¡¤°ñ¼öÀÌÇü¼ºÁõ µî Ç÷¾×Áúȯ

ÀüÈ­ ¿¹¾à 1577-1801
±³¼ö´Ô»çÁø

(ÁÖ°£) Áø·á½Ã°£Ç¥ (2025-01-13 ~ 2025-01-18)

Áø·á½Ã°£Ç¥
Áø·á½Ã°£ ¿ù È­ ¼ö ¸ñ ±Ý Åä
¿ÀÀü ¿Ü·¡Áø·á¿Ü·¡Áø·á¿Ü·¡Áø·á
¿ÀÈÄ ¿Ü·¡Áø·á
±³¼ö´Ô »çÁø

±âº»Á¤º¸

ÇзÂ

ÇзÂ

ÇѸ²´ëÇб³ ÀÇ°ú´ëÇÐ ÀÇÇйڻç(MD, Ph.D)

°æ·Â

°æ·Â

Çö) ÇѸ²´ëÇб³ÀÇ·á¿ø Áß¾ÓÀÓ»óÀÇÇבּ¸¼Ò ¼ÒÀå

Çö) ÇѸ²´ëÇб³¼º½Éº´¿ø ÀÓ»ó½ÃÇè¼¾ÅÍÀå

Weil Cornell Cancer Center, New York, USA, Visiting Professor

FHCRC, Research Associate, Seattle, USA

¼­¿ï¾Æ»êº´¿ø Á¾¾çÇ÷¾×³»°ú ÀÓ»ó°­»ç

ÇÐȸȰµ¿

ÇÐȸȰµ¿

Çö) ´ëÇÑÇ׾Ͽä¹ý¿¬±¸È¸(KCSG) ȸÀå, ÀÌ»çȸÀÇÀå

Çö) ´ëÇÑÀÓ»ó½ÃÇè¼¾ÅÍÇùÀÇȸ(KACTC) ȸÀå

´ëÇÑÀ§¾ÏÇÐȸ Çö)»óÀÓÀÌ»ç

´ëÇÑÁ¾¾ç³»°úÇÐȸ Çö)À±¸®À§¿øÀå, ±âȹÀÌ»ç

´ëÇÑÇ÷¾×ÇÐȸ ±³À°¼ö·ÃÀÌ»ç, »çȸºÀ»ç±³À°ÀÌ»ç

°ú±âºÎ »ý¸í°øÇבּ¸¿ø Çö)¹ÙÀÌ¿À±ÔÁ¦À§¿ø

±¹°¡Ç׾Ͻžళ¹ß»ç¾÷´Ü Çö)ÀÚ¹®À§¿ø

±¹¹Î°Ç°­º¸Çè°ø´Ü Çö)¾àÁ¦±Þ¿©Æò°¡À§¿ø, Çö)»êÁ¤Æ¯·ÊÀ§¿ø

´ëÇѾÏÇÐȸ °Ç°­º¸ÇèÁ¤Ã¥À§¿øÀå

½ÄÇ°ÀǾàÇ°¾ÈÀüó Çö)Ç×¾ÏÁ¦Àü·«ÀÚ¹®À§¿ø, Çö)Áß¾Ó¾à»ç½ÉÀÇÀ§¿ø, Çö)½É¼Ó½ÉÀÇÀÚ¹®À§¿ø

°Ç°­º¸Çè½É»çÆò°¡¿ø Çö)¾ÏÁúȯ½ÉÀÇÀ§¿ø

¼ö»óÀÌ·Â

¼ö»óÀÌ·Â

¹Ì±¹Ç÷¾×ÇÐȸ ¿ì¼ö³í¹®»ó

ÇѸ²´ëÇб³ Çмú»ó

³í¹®

Predictive Value of the nProfiler 1 Assay for the Efficacy of Adjuvant S-1-Based Doublet Chemotherapy in Stage III Gastric Cancer: A Post-Hoc Analysis of a Randomized Phase III Trial / ^^¿µ¹® Á¦¸ñÀ» ¹Ýµå½Ã ±âÀçÇϽñ⠹ٶø´Ï´Ù. (Cancer research and treatment)

Varlitinib and Paclitaxel for EGFR/HER2 Co-Expressing Advanced Gastric Cancer: a Multicenter Phase Ib/II Study (K-MASTER-13) (Cancer Research and Treatment)

Association between Tumor Size at the Time of Disease Progression and Survival Outcomes / ^^¿µ¹® Á¦¸ñÀ» ¹Ýµå½Ã ±âÀçÇϽñ⠹ٶø´Ï´Ù. (Cancer research and treatment)

Pharmacokinetics of Vancomycin in Healthy Korean Volunteers and Monte Carlo Simulations to Explore Optimal Dosage Regimens in Patients with Normal Renal Function (Antibiotics)

Nationwide precision oncology pilot study: KOrean Precision Medicine Networking Group Study of MOlecular profiling-guided therapy based on genomic alterations in advanced solid tumors (KOSMOS) KCSG AL-20-05 (ESMO OPEN)

Precision Dosing of Meropenem in Adults with Normal Renal Function: Insights from a Population Pharmacokinetic and Monte Carlo Simulation Study (Antibiotics)

Neoadjuvant Docetaxel, Oxaliplatin, and S-1 Plus Surgery and Adjuvant S-1 for Resectable Advanced Gastric Cancer: Updated Overall Survival Outcomes From Phase III PRODIGY (JOURNAL OF CLINICAL ONCOLOGY)

Liposomal irinotecan, oxaliplatin, and S-1 as first-line therapy for patients with locally advanced or metastatic pancreatic adenocarcinoma (NASOX): A multicenter phase I/IIa study (EUROPEAN JOURNAL OF CANCER)

FDA regulatory considerations for oncology drug development (PHARMACOLOGY RESEARCH & PERSPECTIVES)

Early dose reduction of dasatinib does not compromise clinical outcomes in patients with chronic myeloid leukemia: A comparative analysis of two prospective trials (LEUKEMIA RESEARCH)
À§¾Ï ÀÓ»óÁø·áÁöħ (Çѱ¹ÀÓ»ó¾ÏÇÐȸ)

À§¾ÏÇ¥ÁØÁø·á±Ç°í¾È (´ëÇÑÀÇÇÐȸ)

ȯ¿ì¿Í °¡Á·À» À§ÇÑ Ç÷¾× Áúȯ ¼Ò°³¼­ (´ëÇÑÇ÷¾×ÇÐȸ)

Ç÷¾×ÇÐ / Hematology ((ÁÖ)¹ü¹®¿¡µàÄÉÀ̼Ç)

RECTAL CANCER-a multidisciplinary approach to management (Intech)

Ç÷¾×ÇÐ / hematology (E*public)